NRX Pharmaceuticals (NRXP)

• Market cap: $18.5M
• 1 day: -2.55%
• 5 days: -1.92%
• 1 month: 20.47%
• 3 months: -10.00%
• 6 months: -36.51%
• Year to date: -69.34%
• 1 year: -67.24%
• 5 years: -99.35%
• 10 years: -99.35%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

4,600% more call options, than puts

Call options by funds: $94K | Put options by funds: $2K

1.83% more ownership

Funds ownership: 4.81% [Q2] → 6.64% (+1.83%) [Q3]

0% more funds holding

Funds holding: 18 [Q2] → 18 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

5% less capital invested

Capital invested by funds: $1.27M [Q2] → $1.21M (-$64.6K) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $19 1,142% upside
• Avg. target: $32 1,959% upside
• High target: $45 2,841% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Edward Woo 36% 1-year accuracy 26 / 73 met price target	2,841% upside $45	Buy Maintained	2 Dec 2024
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target	1,142% upside $19	Buy Reiterated	25 Nov 2024
D. Boral Capital Jason Kolbert 27% 1-year accuracy 41 / 153 met price target	1,926% upside $31	Buy Maintained	15 Nov 2024
EF Hutton Jason Kolbert 27% 1-year accuracy 41 / 153 met price target	1,926% upside $31	Buy Maintained	30 Oct 2024